Search the Newsreel

Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target

MediWound Ltd. (MDWD) reported Q2 2026 revenue of $3.09–3.10M, with a net loss of $7.39M and shares down 5.4% for the quarter. The company stated that its therapy, EscharEx, is targeting a $4 billion U.S. non-surgical tissue repair market, which it identifies as its …

MediWound (NASDAQ:MDWD) Issues Earnings Results

A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $22

A. G. P. has reiterated its Buy rating for MediWound (MDWD.US) and maintained its price target of $22. This suggests a continued positive outlook from the analyst firm regarding the company's stock performance.

MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...

MediWound Ltd (MDWD) reaffirmed its full-year 2026 revenue guidance, citing strong NexoBrid sales and progress in the EscharEx Phase 3 trial. Despite a Q2 revenue decline and increased operating loss, the company anticipates future growth from the expanded EscharEx market assessment and new agreements. …

Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise

MediWound Ltd. (MDWD) exceeded Q2 2026 revenue forecasts, reporting $3.1 million against an expected $2.89 million, leading to a 1.87% rise in pre-market shares. The company reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, anticipating stronger performance in the second …

MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates

MediWound (NASDAQ: MDWD) revenue drops in H1 2026 but guidance held

MediWound Ltd. (NASDAQ: MDWD) reported a significant revenue drop in the first half of 2026, with total revenues falling to $4.6 million from $9.7 million in the prior-year period, primarily due to lower development services revenue. Despite this, the company reaffirmed its full-year 2026 …

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MediWound Ltd. announced its second-quarter 2026 financial results, reporting $3.1 million in revenue and reaffirming its full-year 2026 revenue guidance of $24–26 million. The company highlighted significant progress in its EscharEx Phase III VALUE trial, with interim assessment and enrollment completion expected by Q1 …

MediWound Q2 2026 Earnings Preview

* MediWound (MDWD [https://seekingalpha.com/symbol/MDWD]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.77 [https://seekingalpha.com/symbol/MDWD/earnings/estimates] (+37.4% Y/Y) and the consensus Revenue Estimate is $2.59M (-54.6% Y/Y). * Over the last 2 years, MDWD …

Technical Reactions to MDWD Trends in Macro Strategies

This article analyzes Mediwound Ltd. (NASDAQ: MDWD) using AI models to provide technical insights and trading strategies. It highlights a near-term weak sentiment that may lead to a resumption of long-term weakness, identifying a mid-channel oscillation pattern and a favorable 35.0:1 risk-reward setup. Three …

Earnings Preview: MediWound to Report Financial Results Pre-market on August 13

MediWound (NASDAQ:MDWD) is scheduled to announce its quarterly earnings results before the market opens on Tuesday, August 13th. Analysts predict the company will report earnings of ($0.11) per share for the current quarter. Investors will be watching for the actual results and any forward-looking …

Mediwound Ltd (MDWD) Stock News Today

This article from TradingKey provides current stock information for Mediwound Ltd (MDWD), including its latest stock price, market capitalization, and a general overview of its financials and news. It indicates that more news will be available soon and encourages users to stay tuned for …

MediWound (MDWD) Expected to Release Earnings on Thursday

MediWound (MDWD) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts anticipate a loss of $0.76 per share and revenue of $2.59 million. The company's stock is currently trading near its 12-month low, and despite mixed analyst …

Price to earnings forward of MediWound Ltd. – NASDAQ:MDWD

This article provides a financial snapshot of MediWound Ltd. (NASDAQ: MDWD), specifically focusing on its forward price-to-earnings ratio. It indicates the market status as closed with no current trades. The content is primarily a data page from TradingView.

Mediwound Ltd (MDWD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Mediwound Ltd (MDWD), noting its current score of 5.33 and ranking 66 out of 156 in the Pharmaceuticals industry. It details the company's beta value of 0.18, indicating lower volatility compared to the broader market, and presents …

Trading the Move, Not the Narrative: (MDWD) Edition

This article analyzes Mediwound Ltd. (NASDAQ: MDWD) through the lens of AI-generated trading strategies, focusing on technical signals rather than market narratives. It highlights neutral readings in shorter horizons, a test of support, and a high risk-reward setup targeting a 10.3% gain. The piece …

Mediwound Ltd (MDWD) Financial Health: Profitability & Balance Sheet Analysis

Mediwound Ltd (MDWD) currently holds a financial score of 6.54, placing it 139th out of 155 in the Pharmaceuticals industry. While its financial status is stable, the company exhibits low operating efficiency. Its latest quarterly revenue and net profit have seen significant year-over-year decreases …

MediWound to Report Second Quarter 2026 Financial Results

MediWound Ltd. will announce its financial results for the second quarter ending June 30, 2026, on Thursday, August 13, 2026. Following the release, company management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide …

Mediwound Ltd (MDWD) Institutional Confidence

Mediwound Ltd (MDWD) has an institutional shareholding score of 5.00, placing it 72nd in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 6.90% quarter-over-quarter to 57.77%. Steven Cohen is the largest institutional shareholder with 197.49K shares, representing 1.37% of shares outstanding.

MediWound Schedules August 13 Webcast for Second-Quarter Results

Mediwound Ltd (MDWD) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Mediwound Ltd (MDWD), noting its current valuation score of 7.99, which ranks 113 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -6.88, with other financial metrics like P/B, P/S, and P/CF …

MediWound Ltd. Revenue Breakdown – BOATS:MDWD

MediWound Ltd. (MDWD) generated $16.96 million USD in revenue last year, primarily from its Bio-therapeutic, Non-surgical Solutions segment, a decrease from $20.22 million USD the prior year. The United States was the largest contributor to revenue, accounting for $11.78 million USD, down from $15.46 …

Mediwound Ltd (MDWD) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Mediwound Ltd (MDWD), indicating a current earnings forecast score of 8.33 and an average price target of $32.00 from 6 analysts. It highlights that most analysts recommend a "Buy" trend for the stock, with expected revenue of …

MDWD|Mediwound Ltd|Price:14.665|Chg%:+0.215

This article provides a comprehensive stock analysis of Mediwound Ltd (MDWD), highlighting its strong fundamentals and significant growth potential despite an average market performance. The company's valuation is considered fair, and it has high institutional ownership with multiple analysts rating it as a "Buy" …

Mediwound Ltd (MDWD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mediwound Ltd (MDWD) stock, focusing on its dividend history and stock splits. It indicates that the company has not distributed dividends in the past five years but lists multiple stock split entries, all recorded as a 7-to-1 merger …

Mediwound Ltd (MDWD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mediwound Ltd (MDWD), listing major shareholders and their respective proportions, along with a breakdown of shareholder types. It also provides institutional shareholding data over several quarters and lists related ETFs that hold MDWD. The data reveals key …

MDWD|Mediwound Ltd|Price:14.230|Chg%:-0.040

Mediwound Ltd (MDWD) closed at $14.23, down 0.28% on July 24, 2026. The company, an Israel-based biopharmaceutical firm, is focused on developing therapies for tissue repair and regeneration, including products like NexoBrid and EscharEx. Despite a short-term downward trend expectation, analysts collectively rate the …

(MDWD) Volatility Zones as Tactical Triggers

This article from Stock Traders Daily discusses Mediwound Ltd. (NASDAQ: MDWD), highlighting a mid-channel oscillation pattern and a significant 36.7:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis points to strong near-term …